PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

Journal of Hepatology

Volumn 64, Issue 4, 2016, Pages 800-806

  Papatheodoridis, George ^a   Dalekos, George ^b   Sypsa, Vana ^a   Yurdaydin, Cihan ^c   Buti, Maria ^d   Goulis, John ^e   Calleja, Jose Luis ^f   Chi, Heng ^g   Manolakopoulos, Spilios ^a   Mangia, Giampaolo ^h   Gatselis, Nikolaos ^b   Keskin, Onur ^c   Savvidou, Savvoula ^e   De La Revilla, Juan ^f   Hansen, Bettina E ^g   Vlachogiannakos, Ioannis ^a   Galanis, Kostantinos ^b   Idilman, Ramazan ^c   Colombo, Massimo ^h   Esteban, Rafael ^d   Janssen, Harry L A ^g,i   Lampertico, Pietro ^h   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c ANKARA UNIVERSITY   (Turkey)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁱ TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Entecavir; Hepatitis B; Hepatocellular carcinoma; Tenofovir

Indexed keywords

ENTECAVIR; TENOFOVIR; ANTIVIRUS AGENT; GUANINE;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; CAUCASIAN; CHRONIC HEPATITIS B; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; FEMALE; GENDER; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PAGE B SCORE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; VALIDATION PROCESS; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RISK;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; TENOFOVIR;

EID: 84955316940     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.11.035     Document Type: Article

References (27)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
2. G.V. Papatheodoridis, P. Lampertico, S. Manolakopoulos, and A. Lok Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2010 348 356
3. G.V. Papatheodoridis, S. Manolakopoulos, G. Touloumi, G. Vourli, M. Raptopoulou-Gigi, I. Vafiadis-Zoumbouli, and et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study Gut 60 2011 1109 1116
4. G.V. Papatheodoridis, H.L. Chan, B.E. Hansen, H.L. Janssen, and P. Lampertico Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy J Hepatol 62 2015 956 967
5. European Association for the Study of the Liver European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
6. J. Vlachogiannakos, and G. Papatheodoridis Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy World J Gastroenterol 19 2013 8822 8830
7. M.F. Yuen, Y. Tanaka, D.Y. Fong, J. Fung, D.K. Wong, J.C. Yuen, and et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B J Hepatol 50 2009 80 88
8. V.W. Wong, S.L. Chan, F. Mo, T.C. Chan, H.H. Loong, G.L. Wong, and et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers J Clin Oncol 28 2010 1660 1665
9. H.I. Yang, M.F. Yuen, H.L. Chan, K.H. Han, P.J. Chen, D.Y. Kim, and et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score Lancet Oncol 12 2011 568 574
10. G.L. Wong, H.L. Chan, H.Y. Chan, P.C. Tse, Y.K. Tse, C.W. Mak, and et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment Gastroenterology 144 2013 933 944
11. G.V. Papatheodoridis, G.N. Dalekos, C. Yurdaydin, M. Buti, J. Goulis, P. Arends, and et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir J Hepatol 62 2015 363 370
12. P. Arends, M.J. Sonneveld, R. Zoutendijk, I. Carey, A. Brown, M. Fasano, and et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians Gut 64 2015 1289 1295
13. Rubin DB: Multiple imputation for non response in surveys. New York, 1987.
14. Y. Vergouwe, E.W. Steyerberg, M.J. Eijkemans, and J.D. Habbema Validity of prognostic models: when is a model clinically useful? Semin Urol Oncol 20 2002 96 107
15. L.M. Sullivan D'Agostino RBSr. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials Stat Med 22 2003 1317 1334
16. P. Royston, and D.G. Altman External validation of a Cox prognostic model: principles and methods BMC Med Res Methodol 13 2013 33
17. P.J. Heagerty, T. Lumley, and M.S. Pepe Time-dependent ROC curves for censored survival data and a diagnostic marker Biometrics 56 2000 337 344
18. P. Bedossa, D. Dargere, and V. Paradis Sampling variability of liver fibrosis in chronic hepatitis C J Hepatol 38 2003 1356 1358
19. A.A. Bravo, S.G. Sheth, and S. Chopra Liver biopsy N Engl J Med 344 2001 495 500
20. A.C. Cardoso, R.J. Carvalho-Filho, and P. Marcellin Transient elastography in chronic viral hepatitis: a critical appraisal Gut 60 2011 759 764
21. L. Castera, and M. Pinzani Non-invasive assessment of liver fibrosis: are we ready? Lancet 375 2010 1419 1420
22. E.A. Tsochatzis, K.S. Gurusamy, S. Ntaoula, E. Cholongitas, B.R. Davidson, and A.K. Burroughs Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy J Hepatol 54 2011 650 659
23. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, H. Yuen, and et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
24. T. Hosaka, F. Suzuki, M. Kobayashi, Y. Seko, Y. Kawamura, H. Sezaki, and et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection Hepatology 58 2013 98 107
25. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, I.M. Jacobson, and et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
26. T.C. Tseng, C.J. Liu, H.C. Yang, T.H. Su, C.C. Wang, C.L. Chen, and et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load Gastroenterology 142 2012 1140 1149
27. M.H. Lee, H.I. Yang, J. Liu, R. Batrla-Utermann, C.L. Jen, U.H. Iloeje, and et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles Hepatology 58 2013 546 554